UAB researchers have reversed metabolic dysfunction-associated steatohepatitis (MASH) in mouse models. MASH is a severe liver ...

Accumulation of extracellular matrix (ECM) in liver fibrosis is associated with changes in protein abundance and composition depending upon etiology of the underlying liver disease. Current efforts to ...

The increasing popularity of herbal and dietary supplements has led to an alarming trend : a rise in hospitalizations due to ...

Last patient completed pivotal Phase 3 trial in CHB-associated liver fibrosis in the PRC with data expected in Q1 2025 On track to initiate U.S. Phase 2 trial of F351 in MASH-associated liver fibrosis ...

This illness is now the fastest rising cause of cancer deaths in the UK, but only 33% to 50% of cases are diagnosed at an ...

Alcohol can change how your body breaks down and absorbs medications, causing adverse reactions, and even overdose. Here are ...

The drug will continue to be available for patients with the liver disease in the US under the accelerated approval granted ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...

UAB researchers have reversed metabolic dysfunction-associated steatohepatitis (MASH) in mouse models. MASH is a severe liver disease associated with ...

Medically reviewed by Arno Kroner, DAOM Damiana, scientifically known as Turnera diffusa or Turnera aphrodisiaca, is a ...

The combination of THIO and Libtayo has shown promising results among patients with advanced checkpoint inhibitor-resistant ...

In the wake of an unfavorable advisory committee meeting in September, Intercept Pharmaceuticals’ bid to win full approval ...